Evergreen corporate venture fund of Boehringer Ingelheim. Invests in early-stage biotech startups in oncology, regenerative medicine, infectious diseases, and digital health.
€1M – €15M
Website reachable as of Aug 2026. Focus and check size as listed by the firm, not independently verified.
Learn what Boehringer Ingelheim Venture Fund and similar investors look for:
Biotech pitch guideHealthtech pitch guideTips, programs, and cultural notes
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.